Viemed Healthcare Announces Third Quarter 2025 Financial Results
Viemed Healthcare, Inc. (NASDAQ:VMD) announced strong financial results for the third quarter ended September 30, 2025, with record net revenues of $71.9 million, a 24.0% increase year-over-year. The company reported a net income of $3.5 million ($0.09 per diluted share) and an Adjusted EBITDA of $16.1 million, while also updating its full-year 2025 guidance for net revenue and Adjusted EBITDA. Highlights include strategic acquisition of Lehan’s Medical Equipment, completion of its share repurchase program, and significant growth in ventilator and PAP therapy patient counts.
Viemed Healthcare, Inc. (NASDAQ:VMD) Short Interest Up 29.5% in March
Viemed Healthcare, Inc. (NASDAQ:VMD) experienced a significant 29.5% increase in short interest during March, reaching 450,066 shares, representing 1.5% of the company's shares. This surge in short interest comes after the company reported earnings that beat consensus estimates for EPS but fell slightly short on revenue. Amidst this, insiders, including President Michael Moore, sold shares totaling over $1.2 million in the last quarter, though insiders still retain a 20% ownership.
This Insider Has Just Sold Shares In Viemed Healthcare
Viemed Healthcare (NASDAQ:VMD) President Michael Moore recently sold shares worth US$1.2 million at an average price of US$9.05, representing 7.2% of his holding. While this was the largest insider sale in the last year for the company, it occurred at approximately the current share price, mitigating some concern. Insiders in Viemed Healthcare, which provides home medical equipment and respiratory healthcare services, hold 14% ownership, totaling about US$50 million, indicating a degree of alignment between management and shareholders despite no insider buying in the past year.
Viemed Healthcare Highlights Growth, Diversification and 2026 Guidance at Investor Conference
Viemed Healthcare (NASDAQ: VMD) presented its growth strategy, financial performance, and 2026 guidance at a recent investor conference. The company highlighted its strong financial momentum with a 26% CAGR since going public, $270M revenue in 2025, and a projected 2026 revenue of $310–$320M. Viemed is also diversifying its service offerings, with ventilation revenue decreasing from 87% to 48%, while sleep, oxygen, and other areas expand, addressing a large underserved market and benefiting from a favorable regulatory environment.
If You Invested $1,000 in Viemed Healthcare Inc (VMD)
This article analyzes the historical performance of Viemed Healthcare Inc (VMD) stock, detailing how a $1,000 investment would have fared over one, five, and ten years. It shows that while a $1,000 investment 10 years ago would now be worth $1,241, VMD has underperformed the S&P 500 by a significant margin over the same period. The article also provides an overview of Viemed Healthcare Inc, its business model focusing on in-home clinical care for respiratory conditions, its services, growth strategies including acquisitions, and financial disclosures.
Michael Moore Sells 65,000 Shares of Viemed Healthcare (NASDAQ:VMD) Stock
Viemed Healthcare President Michael Moore sold 65,000 shares of the company's stock on March 20th for $570,050, reducing his stake by almost 4%. This brings his total sales over three days to 136,802 shares. The company's stock, NASDAQ:VMD, traded at $8.71 with high volume, has a market cap of approximately $336 million, and analysts currently rate it as "Hold."
Viemed Healthcare (NASDAQ:VMD) President Sells $370,536.72 in Stock
Viemed Healthcare (NASDAQ:VMD) President Michael Moore sold 40,232 shares of the company's stock valued at $370,536.72, reducing his ownership by 2.38%. This sale was part of a series of transactions including additional sales on March 18th and 20th. Following these insider sales, the company's shares traded down 5.5% on increased volume, even though Viemed Healthcare recently reported earnings that beat analyst estimates but slightly missed revenue projections.
Viemed Healthcare (NASDAQ:VMD) President Michael Moore Sells 31,570 Shares
Viemed Healthcare (NASDAQ:VMD) President Michael Moore sold 31,570 shares of the company's stock on March 18th for approximately $297,389.40, reducing his ownership by 1.83%. This sale is part of a larger pattern of insider selling totaling 136,802 shares between March 18-20. The company's stock fell 5.5% to $8.71 on heavy volume, following recent mixed quarterly results and a "Hold" consensus rating from analysts, despite a "Strong-Buy" upgrade from one firm.
Viemed Healthcare president Moore sells shares worth $1.23m
Michael Moore, President of Viemed Healthcare, Inc. (NASDAQ:VMD), sold 136,802 common shares for approximately $1.23 million between March 18 and March 20, 2026. Despite these sales, Moore retains significant indirect and direct ownership in the company, which recently reported a Q4 2025 EPS beat but a revenue miss. InvestingPro analysis suggests the stock may be undervalued.
Viemed Healthcare (VMD) president’s LLC sells 136,802 common shares
Viemed Healthcare President Michael Moore reported indirect sales of 136,802 Common Shares through Moore Faster LLC between March 18 and March 20, 2026. The shares were sold at weighted-average prices ranging from $8.77 to $9.42, with each price representing multiple transactions. Following these sales, Moore Faster LLC holds 1,585,812 Common Shares indirectly, and Michael Moore directly holds 189,090 Common Shares.
Viemed Healthcare Insider Sold Shares Worth $1,237,976, According to a Recent SEC Filing
An insider at Viemed Healthcare, Inc. (VMD) sold shares valued at $1,237,976, according to a recent SEC filing. The article, published by MT Newswires, provides this financial transaction detail without further specifics on the insider or the nature of the sale. Viemed Healthcare is a provider of home medical equipment and post-acute respiratory healthcare services in the United States.
[144] VIEMED HEALTHCARE, INC. SEC Filing
Viemed Healthcare, Inc. (VMD) reported a Form 144 SEC filing, indicating a sale of 31,570 common shares by MOORE FASTER LLC on March 18, 2026, for proceeds of $297,345.20. The transaction was brokered by Morgan Stanley Smith Barney LLC. Both Rhea-AI and Capital Markets Analyst sentiments deemed the filing and its market impact as neutral, noting the routine nature and small size of the transaction relative to the market float.
VMD: Diversified home-based care platform posts record growth, driven by sleep and maternal health
Viemed Healthcare, Inc. (VMD) is experiencing rapid and profitable growth in its home-based care platform. This expansion is attributed to service diversification, technology adoption, and strategic M&A, with particular momentum in sleep, maternal health, and staffing divisions. Favorable regulatory conditions and reimbursement trends are further supporting the company's growth.
[144] VIEMED HEALTHCARE, INC. SEC Filing
This article provides details of a Form 144 SEC filing by Viemed Healthcare, Inc. (VMD) which indicates a proposed sale of 31,570 shares of common stock with an aggregate market value of $297,345.20. The securities were acquired on December 22, 2017, through a merger/acquisition, and the sale is being handled by Morgan Stanley Smith Barney LLC. The filing shows a neutral sentiment and is dated March 18, 2026.
Viemed Healthcare (VMD) grows to $270M revenue and guides up for 2026
Viemed Healthcare (VMD) reported strong 2025 financial results with $270 million in net revenue and $61 million in Adjusted EBITDA, marking its ninth consecutive year of positive net income. The company provided optimistic guidance for 2026, projecting net revenue between $310 million and $320 million, and Adjusted EBITDA between $65 million and $69 million. Viemed highlights its diversified, capital-light, home-based care model, with significant growth in its sleep therapy segment and a strong balance sheet supporting further expansion and shareholder returns.
Viemed Healthcare to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Viemed Healthcare, a national provider of home-based healthcare solutions, announced it will present and host one-on-one meetings at Sidoti's Small-Cap Virtual Investor Conference on March 18-19, 2026. The company, trading as NASDAQ:VMD, focuses on respiratory, chronic care, and women's health products and services. The presentation is scheduled for March 19 at 1:45 p.m. ET, and investors can register for the event and one-on-one meetings online.
Investors can stream Viemed’s Sidoti small-cap presentation free
Viemed Healthcare (NASDAQ: VMD) will present and host one-on-one investor meetings at Sidoti's Small-Cap Virtual Investor Conference on March 18-19, 2026. The company's presentation is scheduled for 1:45 p.m. ET on March 19, 2026, and registration for both the presentation and one-on-one meetings is free and open online. The announcement follows recent disclosures of record 2025 financial results and a new share repurchase program.
VieMed Healthcare posts March 2026 investor deck with $315M 2026 revenue guidance, $65M–$69M Adj. EBITDA
VieMed Healthcare released an investor deck detailing record 2025 results and providing 2026 guidance. The company reported $270.3M net revenue and $61.4M Adjusted EBITDA for 2025, and projects $310M–$320M net revenue and $65M–$69M Adjusted EBITDA for 2026. Key highlights include significant PAP patient growth, a new share repurchase program, and strategic priorities like M&A and AI integration.
Viemed Healthcare to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Viemed Healthcare, Inc. announced its participation in Sidoti's Small-Cap Virtual Investor Conference on March 18-19, 2026. The company will deliver a presentation on March 19th at 1:45 p.m. ET and conduct virtual one-on-one meetings with investors on both days. Registration for the event is free and open to all interested parties.
VMD - Viemed Healthcare Inc Latest Stock News & Market Updates
This page provides a comprehensive overview of Viemed Healthcare Inc. (VMD) stock news and market updates, aggregating company-specific information for investors. It covers financial results, strategic transactions, capital allocation, acquisitions like Lehan’s Medical Equipment, and conference presentations. The page also features an archive of news items, outlining past financial performances, major acquisitions, and regulatory victories.
Viemed Healthcare Releases Updated March 2026 Investor Presentation
Viemed Healthcare (VMD) has released an updated investor presentation dated March 2026, intended for investors and analysts, which outlines its position as a national leader in home-based clinical care, particularly in complex respiratory services. The company emphasizes its technology-enabled care model and aims to present its growth narrative and financial metrics. Analysts currently rate VMD stock as a Buy with a $9.00 price target, and TipRanks’ AI Analyst, Spark, rates it as Outperform due to solid financial fundamentals and a constructive earnings outlook.
VMD SEC Filings - Viemed Healthcare Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Viemed Healthcare Inc. (VMD) SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event forms, and insider trading documents. It highlights key events like equity compensation for executives, credit agreement amendments, and financial results, with AI-generated summaries to aid interpretation. The platform aims to make regulatory information accessible for both experienced and new investors.
Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 4Q 2025
Stonegate Capital Partners has updated its coverage on Viemed Healthcare, Inc. (VMD), highlighting the company's strong financial performance in FY25 with 21% net revenue growth to $270.3M and record adjusted EBITDA of $61.4M. The report emphasizes the increasing contribution of sleep and resupply services, which are improving recurring revenue quality and reducing regulatory sensitivity, alongside the strategic benefit of the Lehan's acquisition for broader market exposure. Despite some short-term regulatory friction, Viemed ended the year with a significant increase in free cash flow, and Stonegate suggests that durable growth remains undervalued.
Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. 4Q 2025
Stonegate Capital Partners has updated its coverage on Viemed Healthcare, Inc. (NASDAQ: VMD), highlighting its strong FY25 performance with 21% revenue growth to $270.3M and a record adjusted EBITDA of $61.4M. The company's growth was driven by platform momentum, contributions from Lehan's, and increasing adoption of sleep resupply, despite temporary friction from updated NCD guidelines for ventilator patients. The report suggests Viemed's durable growth and improving recurring revenue quality remain underappreciated by the market.
Viemed Healthcare authorizes share buyback program through 2027
Viemed Healthcare, Inc. announced a new share repurchase program, effective through March 2027, to buy back up to 5% of its outstanding common shares. This marks the company's fourth such program, reflecting management's confidence in its financial health and commitment to capital allocation, especially after strong 2025 financial results. InvestingPro analysis suggests the stock is undervalued, supported by aggressive share buybacks and a low P/E ratio.
Viemed Healthcare, Inc. (NASDAQ:VMD) Q4 2025 Earnings Call Transcript
Viemed Healthcare, Inc. held its Q4 2025 earnings call, reporting record revenue of $270.3 million and adjusted EBITDA of $61.4 million for the full year 2025. The company highlighted significant growth in sleep and resupply segments due to strong market demand and the successful integration of Lehan’s Medical Equipment, which expanded its maternal health offerings. Viemed also provided a positive outlook for 2026, projecting revenue between $310 million and $320 million, attributing its stability and growth to a diversified business model, strong compliance, and effective capital allocation including a new share repurchase program.
Segall Bryant & Hamill LLC Invests $1.97 Million in Viemed Healthcare, Inc. $VMD
Segall Bryant & Hamill LLC has initiated a new position in Viemed Healthcare (NASDAQ:VMD), acquiring 289,446 shares valued at approximately $1.97 million during the third quarter, representing about 0.76% ownership. Viemed Healthcare previously beat EPS estimates but missed revenue expectations, and institutional investors now hold around 74.24% of the stock. Analyst ratings for VMD are currently mixed, with an average "Hold" rating.
Viemed Healthcare (VMD) TTM Earnings Growth Of 32.6% Tests Bearish Longer Term Narrative
Viemed Healthcare (VMD) reported strong Q4 2025 results with revenue of US$76.2 million and a trailing twelve-month earnings growth of 32.6%. This recent growth challenges a five-year earnings decline, with profitability improving over recent quarters but a modest net margin of 5.5% raising concerns about potential pressure from new growth areas and cost increases. The stock's valuation shows a wide range, with a P/E below industry average but a DCF fair value significantly lower than its current share price, indicating uncertainty for investors.
Viemed (VMD) Q4 2025 Earnings Call Transcript
Viemed Healthcare, Inc. (VMD) reported record full-year revenue and adjusted EBITDA for 2025, driven by significant diversification into sleep, resupply, and maternal health segments. The company successfully integrated the Lehan acquisition, which contributed positively to net income and expanded their maternal health offerings. Despite operational headwinds from updated National Coverage Determinations affecting ventilator patient growth, Viemed maintains a strong financial position with a new share repurchase program and projects 17% revenue growth for 2026.
Home-care firm Viemed plans to buy back up to 1.93M shares by 2027
Viemed Healthcare (NASDAQ:VMD) announced a share repurchase program authorizing the purchase of up to 1,930,131 common shares, approximately 5% of its issued shares, effective through March 2027. This marks the company's fourth such program, following previous repurchases of approximately 4.5 million shares totaling $26.3 million. The decision is supported by Viemed's record 2025 revenue and Adjusted EBITDA, doubled free cash flow, and a strong balance sheet with $13.5 million cash and effectively no net debt.
Viemed Healthcare (NASDAQ:VMD) Issues Earnings Results
Viemed Healthcare (NASDAQ:VMD) reported its quarterly earnings, beating the EPS consensus by $0.02 with $0.14 per share, despite revenue of $76.18 million falling short of expectations. Following the announcement, the stock rose by 1.5% to $9.08. Analysts maintain a "Hold" consensus, although institutional ownership is high at 74.24% and one firm recently upgraded the stock to "strong-buy."
Record 2025 growth at Viemed (NASDAQ: VMD) plus new share buyback
Viemed Healthcare (NASDAQ: VMD) reported record financial results for 2025, with net revenue increasing 21% to $270.3 million and Adjusted EBITDA reaching $61.4 million. The company also announced a new share repurchase program, authorizing the buyback of up to 1,930,131 common shares, approximately 5% of outstanding shares, effective through March 2027. For 2026, Viemed projects continued growth with net revenue guidance between $310 million and $320 million and Adjusted EBITDA between $65 million and $69 million.
Viemed Healthcare 10-K: Revenue $270.3M, EPS $0.37
Viemed Healthcare (VMD) reported strong fiscal 2025 results, with revenue increasing to $270.3 million and diluted earnings per share reaching $0.37. This growth was fueled by a significant increase in equipment and supply sales, along with strategic program rollouts and acquisitions. The company also expanded its patient base and workforce, reinforcing its focus on technology-enabled home clinical care.
Viemed Healthcare Announces Third Quarter 2025 Earnings Conference Call Details
Viemed Healthcare, Inc. (NASDAQ: VMD) has announced it will host its Third Quarter 2025 Earnings Conference Call on Thursday, November 6, 2025, at 11:00 a.m. ET. Interested parties can participate via a toll-free number or an international number, or through a live audio webcast. A replay will be available on the company's investor relations website following the call.
Understanding the Setup: (VMD) and Scalable Risk
This article provides an analysis of Viemed Healthcare Inc. (NYSE: VMD), highlighting strong near-term sentiment but a neutral mid and long-term outlook with elevated downside risk. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels. The piece emphasizes institutional-grade analysis and real-time trading signals offered by Stock Traders Daily.
Viemed Healthcare, Inc. (VMD) Stock Report: Strong Buy Ratings Highlight 51% Potential Upside
Viemed Healthcare, Inc. (VMD) is attracting investor interest with strong buy ratings and an estimated 51% potential upside. Analysts have set an average target price of $13.00 for the company, which specializes in home medical equipment and post-acute respiratory healthcare services. Viemed's stock is trading favorably above its moving averages, supported by robust revenue growth and solid operational performance, making it a compelling investment case in the healthcare sector.
VMD Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Viemed Healthcare Inc (VMD), including its income statement, balance sheet, and cash flow statement. It highlights key financial metrics for FY2024, such as strong revenue growth of 22.5%, a low debt-to-equity ratio, and moderate profitability, while also detailing quarterly and annual performance trends and financial health indicators like the Altman Z-Score and Piotroski F-Score. The company's financial profile is rated 51/100, indicating moderate overall financial health.
Viemed Healthcare (VMD) Expected to Announce Quarterly Earnings on Wednesday
Viemed Healthcare (NASDAQ:VMD) is projected to release its Q4 2025 earnings after market close on Wednesday, March 4th, with analysts anticipating $0.12 EPS on $77.70 million in revenue. The company's stock currently trades around $8.61, with a market cap of $327.35 million, and has received mixed analyst ratings, including a recent "strong-buy" upgrade from Wall Street Zen. Institutional investors hold approximately 74.24% of the shares.
Viemed Healthcare Announces Year End 2025 Earnings Conference Call Details
Viemed Healthcare, Inc. (NASDAQ:VMD) announced it will host its Year End 2025 earnings conference call on Thursday, March 5, 2026, at 11:00 a.m. ET. Interested parties can participate via dialing in or through a live audio webcast, with a replay available on the company's investor relations website afterward. Viemed Healthcare is a national provider of technology-enabled, home-based healthcare solutions.
Home-care provider Viemed sets Year End 2025 earnings call date
Viemed Healthcare (NASDAQ: VMD), a provider of home-based healthcare solutions, announced it will host its Year End 2025 earnings conference call on March 5, 2026, at 11:00 a.m. ET. Interested parties can join via dial-in numbers or a live audio webcast, with a replay available on the company's investor relations website afterward. The announcement led to a mild positive market reaction, with VMD gaining 1.81%, adding approximately $6 million to its valuation.
Viemed Healthcare Announces Year End 2025 Earnings Conference Call Details
Viemed Healthcare, Inc. (NASDAQ: VMD) has announced that it will host its Year End 2025 earnings conference call on Thursday, March 5, 2026, at 11:00 a.m. ET. Interested parties can participate by dialing the provided numbers for US toll-free or international calls, or via a live audio webcast. A replay will also be available on the company's Investor Relations website.
Viemed Healthcare Announces Year End 2025 Earnings Conference Call Details
Viemed Healthcare, Inc. announced details for its Year End 2025 earnings conference call. The call is scheduled for Thursday, March 5, 2026, at 11:00 a.m. ET, and will discuss the company's financial results. Interested parties can join via phone or a live audio webcast, with a replay available afterward on the company's investor relations website.
Viemed Healthcare, Inc. (VMD) Investor Outlook: Exploring A 54% Potential Upside
Viemed Healthcare, Inc. (VMD) is attracting investor attention with its strong growth and a potential upside of 54.39% according to analyst targets. The company, a key player in respiratory healthcare services, has shown robust revenue growth of 24.00% and positive financial indicators despite a lack of traditional P/E or PEG ratios. Analysts are overwhelmingly positive, with two buy ratings and no hold or sell recommendations, suggesting a promising outlook for the stock.
Viemed Healthcare (NASDAQ:VMD) Upgraded at Wall Street Zen
Viemed Healthcare (NASDAQ:VMD) was upgraded by Wall Street Zen from a "buy" to a "strong-buy" rating despite other analysts maintaining a "Hold" consensus. The stock opened at $8.28, up 1.5%, with a market capitalization of $314.8 million and a P/E of 25.09. Institutional investors own 74.24% of the stock, with recent modest inflows from several funds.
Thrivent Financial for Lutherans Sells 1,238,000 Shares of Viemed Healthcare, Inc. $VMD
Thrivent Financial for Lutherans significantly reduced its stake in Viemed Healthcare, Inc. (NASDAQ:VMD) by selling 1,238,000 shares, bringing its total ownership to 384,000 shares, valued at approximately $2.61 million. Despite this reduction, other institutional investors increased their holdings, with overall institutional ownership standing at 74.24%. The article also notes Viemed Healthcare's current market performance, financial metrics, and a "Hold" consensus rating from analysts.
Viemed Healthcare, Inc. (NASDAQ:VMD) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Viemed Healthcare's stock has risen by 35% in three months, but its fundamentals, particularly its 10% Return on Equity (ROE) and five-year net income shrinkage of 17%, present a mixed picture. While the company retains most of its profits, its low ROE and declining earnings suggest that these reinvestments might not be effectively benefiting investors, especially when compared to the industry's 2.9% earnings growth. Analysts, however, anticipate future earnings growth for Viemed Healthcare.
Viemed Healthcare, Inc. (NASDAQ:VMD) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Viemed Healthcare's stock has risen 35% in the past three months, but its fundamentals, particularly its 10% Return on Equity (ROE), appear mixed. Despite reinvesting all profits, the company's net income has shrunk by 17% over five years, contrasting with the industry's 2.9% growth. While current performance is ambiguous, analysts forecast future earnings growth for the company.
Technical Reactions to VMD Trends in Macro Strategies
This article analyzes Viemed Healthcare Inc. (NYSE: VMD) using AI models to provide technical reactions and macro strategies. It identifies a neutral sentiment across all time horizons, suggesting a wait-and-see approach, and outlines specific position trading, momentum breakout, and risk hedging strategies with entry and exit points, targets, and stop losses. The analysis highlights a 32.0:1 risk-reward short setup if resistance holds.
Viemed Healthcare, Inc. (NASDAQ:VMD) is favoured by institutional owners who hold 58% of the company
Institutional investors hold a significant 58% ownership in Viemed Healthcare, Inc. (NASDAQ:VMD), making the company's stock vulnerable to their trading decisions. The top 13 shareholders collectively own 50% of the company, and insiders hold a 13% stake, aligning their interests with shareholders. The article suggests investigating analyst recommendations and revenue growth for further insights into the company's performance.
Trading the Move, Not the Narrative: (VMD) Edition
This article analyzes Viemed Healthcare Inc. (NYSE: VMD) with a neutral sentiment across all time horizons, suggesting a wait-and-see approach. It highlights resistance testing and an exceptional risk-reward short setup targeting 9.0% downside. The analysis provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles.
